Patents Assigned to OraVax, Inc.
  • Urease-based vaccine and treatment for helicobacter infection
    Patent number: 6290962
    Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection and treatment of Helicobacter infection by administering to the host an immunogenically effective amount of a Helicobacter urease or urease subunits as antigen. Vaccine compositions are also provided.
    Type: Grant
    Filed: February 23, 1994
    Date of Patent: September 18, 2001
    Assignee: OraVax, Inc.
    Inventors: Pierre Michetti, Iréne Corthésy-Theulaz, André Blum, Catherine Davin, Rainier Haas, Jean-Pierre Kraehenbuhl, Emilia Saraga
  • PCR amplification of rearranged genomic variable regions of immunoglobulin genes
    Patent number: 6258529
    Abstract: The invention features methods for isolating immunoglobulin variable region genes, and the use of these genes in the production of chimeric and isotype switched antibodies. The invention also features substantially pure DNA encoding a variable region of the antibody produced by hybridoma cell line HNK-20, and chimeric antibodies containing this variable region.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: July 10, 2001
    Assignee: OraVax, Inc.
    Inventors: José Berdoz, Jean-Pierre Kraehenbuhl
  • Clostridium difficle toxins as mucosal adjuvants
    Patent number: 5919463
    Abstract: The invention features methods and compositions for inducing protective and/or therapeutic immune responses to an antigen in a mammal. In these methods, an antigen is administered to the mammal with a toxin of a Clostridium (e.g., C. difficile), or a fragment or derivative thereof having adjuvant activity.
    Type: Grant
    Filed: October 16, 1995
    Date of Patent: July 6, 1999
    Assignee: OraVax, Inc.
    Inventors: William D. Thomas, Jr., Thomas P. Monath, Zhenxi Zhang, Francisco Javier Torres-Lopez, Wende Lei, David M. Lyerly, James S. Moncrief
  • Use of bluetongue virus proteins as vaccine components
    Patent number: 5833995
    Abstract: A protective effect against bluetongue infection in susceptible mammals which is obtained by innoculating said mammals with a polypeptide comprising at least an antigenic portion of bluetongue virus structural protein VP2 in antigenic form produced by transforming a host with a recombinant expression vector having a DNA segment coding for said polypeptide.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: November 10, 1998
    Assignees: Oravax, Inc., Natural Environmental Research Council
    Inventors: Polly Roy, Timothy J. French
  • Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
    Patent number: 5733740
    Abstract: An isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic polypeptide of the present invention and detecting the binding of the antigen or fragment and the antibody. The detection of a strain expressing the TagA antigen is an indication of predisposition to peptic ulceration and gastric carcinoma. A mutant H. pylori not expressing a functional TagA antigen is also provided.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: March 31, 1998
    Assignees: Vanderbilt University, OraVax, Inc.
    Inventors: Timothy L. Cover, Martin J. Blaser, Harry Kleanthous, Murali K. R. Tummuru
  • Oral immunization with multiple particulate antigen delivery system
    Patent number: 5690938
    Abstract: Method of inducing a mucosal and or/systemic immune response in a host, comprising the step of administering to the host an effective amount of a Bluetongue antigen in the form of virus like and/or virus core like particles. Vaccines are also provided.
    Type: Grant
    Filed: October 5, 1993
    Date of Patent: November 25, 1997
    Assignees: Oravax, Inc., Natural Environment Research Council
    Inventors: Thomas H. Ermak, Jacques Pappo, Farshad Guirakhoo, Richard D. Nichols, Jr., Thomas P. Monath, Polly Roy
  • Production of antigens by self-assembly of polypeptide components
    Patent number: 5686270
    Abstract: Antigens are produced by self-assembly of polypeptide components. The production of bluetongue virus antigens (BTV) in the form of assembled particles comprising separate polypeptide components, particularly proteins VP2, VP3, VP5 and VP7 is described.
    Type: Grant
    Filed: June 21, 1995
    Date of Patent: November 11, 1997
    Assignees: Oravax, Inc., Natural Environmental Research Council
    Inventors: Polly Roy, Timothy J. French
  • Oral treatment of helicobacter infection
    Patent number: 5538729
    Abstract: Method of eliciting in a mammalian host a protective immune response to Helicobacter infection, by orally administering to the host an immunogenically effective amount of Helicobacter antigen. Vaccine compositions are also provided.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: July 23, 1996
    Assignee: OraVax, Inc.
    Inventors: Steven J. Czinn, John G. Nedrud
  • Monoclonal IgA antibody specific for respiratory syncytial virus, a hybridoma cell line that produces this antibody amd methods of using the antibody to diagnose RSV infection
    Patent number: 5534411
    Abstract: A new hybridoma cell line HNK20 which secretes a monoclonal IgA antibody to respiratory syncytial virus is disclosed. The antibody has diagnostic uses in respect of Respiratory Syncytial Virus.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: July 9, 1996
    Assignee: OraVax, Inc.
    Inventor: Richard A. Weltzin